Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5584028 | Seminars in Arthritis and Rheumatism | 2017 | 9 Pages |
Abstract
Switching bDMARD therapies is a recommended strategy for patients who experience treatment failure. Many factors must be considered for determining which agent to switch to including PsA disease characteristics, comorbidities, cardiometabolic risk factors, treatment history, and patient preference. Switching between TNFis can be effective for many patients, but bDMARDs with different mechanisms of action may be superior alternatives.
Keywords
TNFiOMERACTTNFPSAEULAROTISIBDDMARDsACRBDMARDsMDAGRAPPAJanus kinasepsoriatic arthritisMRIinterleukinPASIInflammatory bowel diseaseMagnetic resonance imagingdisease-modifying antirheumatic drugsBiologic therapySPIRITTreatment switchingTreatment failuretumor necrosis factorSystemic lupus erythematosusSLEEuropean League Against Rheumatismpsoriasis area and severity indextumor necrosis factor inhibitorPianoJAKAmerican College of Rheumatology
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Joseph F. MD, MMSc, Benjamin MD, FAAD, Elinor A. MD,